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Abstract This study evaluates whether estimated multidrug
resistance (MDR) levels are dependent on the design of the
surveillance system when using routine microbiological data.
We used antimicrobial resistance data from the Antibiotic
Resistance and Prescribing in European Children (ARPEC)
project. The MDR status of bloodstream isolates of
Escherichia coli, Klebsiella pneumoniae and Pseudomonas
aeruginosa was defined using European Centre for Disease
Prevention and Control (ECDC)-endorsed standardised algo-
rithms (non-susceptible to at least one agent in three or more
antibiotic classes). Assessment of MDR status was based on
specified combinations of antibiotic classes reportable as part
of routine surveillance activities. The agreement betweenMDR
status and resistance to specific pathogen–antibiotic class combi-
nations (PACCs) was assessed. Based on all available antibiotic
susceptibility testing, the proportion of MDR isolates was 31%
for E. coli, 30% for K. pneumoniae and 28% for P. aeruginosa
isolates. These proportions fell to 9, 14 and 25%, respectively,
when based only on classes collected by current ECDC surveil-
lance methods. Resistance percentages for specific PACCs were
lower compared with MDR percentages, except for
P. aeruginosa. Accordingly, MDR detection based on these
had low sensitivity for E. coli (2–41%) and K. pneumoniae
(21–85%). Estimates of MDR percentages for Gram-negative
bacteria are strongly influenced by the antibiotic classes reported.
When a complete set of results requested by the algorithm is not
available, inclusion of classes frequently tested as part of routine
clinical care greatly improves the detection of MDR. Resistance
to individual PACCs should not be considered reflective ofMDR
percentages in Enterobacteriaceae.
Introduction
Bacteria resistant to multiple antibiotics have been identified as a
major challenge for patient management and public health [1, 2].
Multidrug-resistant Gram-negative bacteria (MDR-GNB) are
considered to be particularly worrying because the therapeutic
options are limited [3, 4]. Furthermore, certainMDR-GNB, such
as those producing extended-spectrum beta-lactamases or
carbapenemases encoded on plasmids, are of concern due to their
potential for interspecies plasmid transfer [5, 6].
Large-scale national and international surveillance is an
important tool in monitoring MDR-GNB resistance trends
[7]. At present, most surveillance relies on collecting results
from traditional antibiotic susceptibility testing (AST) to track
resistance epidemiology, including multidrug resistance
(MDR) [8–10]. It is, therefore, important that the comparabil-
ity of isolates identified as MDR by surveillance databases is
established. Standardised algorithms for reporting isolates as
MDR were proposed in 2012 by a group of international ex-
perts, but these rely on a large number of antibiotics being
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included in AST (Table 1) [11]. The selection of antibiotic
classes for routine testing continues to be highly variable
[16–19]. This potentially presents a major challenge for esti-
mating and comparing MDR-GNB prevalence from routine
data, given that individual laboratories may not test all antibi-
otic classes required.
The monitoring of specific pathogen–antibiotic class com-
binations (PACCs) can be an alternative surveillance strategy
to make best use of the available routine data [7, 12–14].
Some PACCs have been suggested as being useful for
MDR-GNB assessment based on the recognition of an asso-
ciation in resistance between different antibiotic classes [15].
Using data on neonatal and paediatric GNB isolates obtain-
ed from the Antibiotic Resistance and Prescribing in European
Children (ARPEC) project, this study evaluates the degree to
which estimated levels of MDR are dependent on surveillance
system design when routine microbiological data are used.
Materials and methods
Data source
The study used data from the ARPEC project, which was co-
funded by the European Commission DG Sanco through the
Executive Agency for Health and Consumers [20, 21].
ARPEC collected anonymised data on antimicrobial resis-
tance between January 2011 and December 2012 from 19
European laboratories located in 12 different countries, each
processing samples for one paediatric department or hospital.
ARPEC requested that participating laboratories reported
AST results for isolates of a specified set of bacterial species,
and that, where possible, laboratories report on specific anti-
biotics. These included antibiotics required for the European
Antimicrobial Resistance Surveillance Network (EARS-Net)
2010 reporting protocol plus some additional antibiotic cate-
gories (Table 1) [12, 22]. The AST results for each antibiotic
tested were reportable as susceptible/intermediate/resistant
(S/I/R) using breakpoints defined by either:
(1) European Committee on Antimicrobial Susceptibility
Testing (EUCAST),
(2) Clinical and Laboratory Standards Institute (CLSI),
(3) British Society for Antimicrobial Chemotherapy
(BSAC) or
(4) Société Française de Microbiologie standards,
depending on which standards were used in each country
[23–27]. Minimal inhibitory concentrations of antibiotics
were not collected. Duplicate isolates (same species with same
antibiogram from the same patient) identified within 4 weeks
of the original isolate were excluded as part of the data collec-
tion protocol.
Target bacteria
This study examined MDR patterns for three GNB, namely
Escherichia coli, Klebsiella pneumoniae and Pseudomonas
aeruginosa.
Interpretation of reported antibiotic susceptibility
Individual antibiotics were grouped into antibiotic classes as
defined by the MDR classification algorithms (Table 1) [11].
Isolates reported as I or R to an antibiotic representative of an
antibiotic class were classified as non-susceptible to that class.
In the case of AST results for multiple antibiotics representa-
tive of one class, the isolate was classified as non-susceptible
if they were reported as I or R to any of the antibiotics tested
from that class. Isolates were defined as MDR-GNB if they
were non-susceptible to ≥3 relevant antibiotic classes [11].
Identification of MDR-GNB bacterial isolates
The proportion of isolates of each of the three species consid-
ered to show MDR was then calculated using three sets of
antibiotic classes (Table 1):
(1) ARPEC set: MDR status was defined by applying the
MDR algorithm and based on information from all clas-
ses reported to ARPEC;
(2) EARS-Net set: MDR status was defined by applying the
MDR algorithm, but based solely on information for
classes included in the EARS-Net protocol;
(3) Routine set: MDR status was defined by applying the
MDR algorithm, and based on antibiotic classes with a
high level of reported results across all ARPEC labora-
tories. Classes were included in this set if AST informa-
tion was available for at least 85% of isolates. The level
of required reporting was chosen to reflect classes rou-
tinely tested for the bacteria of interest in the majority of
laboratories.
As both the EARS-Net and routinely tested classes are
subsets of the ARPEC classes, an isolate classified as MDR
on the basis of either set was also considered to beMDR based
on the ARPEC set.
Evaluation of single PACCs
It was also assessed whether specific PACCs, suggested to be
critical indicators of MDR by European, US and global pro-
fessional and/or public health bodies (Table 1), could identify
MDR-GNB as detected on the basis of all available data; that
is, the ARPEC set [7, 13–15].
The specific PACCs of interest were E. coli and higher-
generation cephalosporins, fluoroquinolones, aminoglycosides
Eur J Clin Microbiol Infect Dis
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and carbapenems, K. pneumoniae and higher-generation cepha-
losporins and carbapenems, andP. aeruginosa and carbapenems.
We defined its sensitivity as the proportion of isolates clas-
sified as susceptible for each PACC among those flagged as
MDR from the ARPEC set, and its specificity as the propor-
tion of isolates classified as non-susceptible for each PACC
that was identified as not MDR from the ARPEC set.
Statistical analysis
All statistical analyses were carried out using Stata® v12.1,
StataCorp, College Station, TX, USA. Whenever 95% confi-
dence intervals (CIs) are given for proportions, these were
calculated by applying an exact method for binomial data.
Results
In total, 685 isolates were included in the analysis (375E. coli,
176 K. pneumoniae, 134 P. aeruginosa).
Antibiotic classes included in the Routine set
The classes with reported AST results for the participating
centres were very diverse, and there was no consistent pattern
of classes among hospitals located in the same geographical
region (data not shown). No laboratory consistently reported
on all classes that were included in the ARPEC protocol.
There was more consistency for the subset of EARS-Net an-
tibiotic classes, with AST results available for at least 85% of
isolates of all three species.
There were several classes for which AST data were also
available for at least 85% of isolates. The additional frequently
tested PACCs includedE. coli andK. pneumoniaeAST results
for penicillins/beta-lactamase inhibitor (91 and 96% of iso-
lates), folate pathway inhibitors (86 and 86%) and
antipseudomonal penicillins/beta-lactamase inhibitor (85 and
85%). These were then included in the Routine set (Table 1).
The only additional ARPEC antibiotic class relevant for
P. aeruginosa MDR classification was monobactams, for
which AST results were reported for only 47% of isolates.
Identification of MDR status according to the EARS-Net,
Routine and ARPEC sets
The proportion of MDR isolates based on the most complete
ARPEC set was 30% (95% CI 27–34%) for all three GNB.
Figure 1 shows the number of isolates classified as MDR
using the EARS-Net set, the Routine set and the ARPEC
set, and the overall proportion estimated as MDR for each
pathogen.
Table 2 shows the proportion estimated as MDR for each
set. Extending the set from the limited EARS-Net set to the
Routine set identified an additional 96 MDR isolates, more
than doubling the estimate of MDR-GNB from 13% (95% CI
11–16%) to 27% (95% CI 24–31%). This was most marked
for E. coli and K. pneumoniae isolates (Fig. 1 and Table 2). A
similar underestimation on the basis of the EARS-Net set was
not observed for P. aeruginosa.
For E. coli andK. pneumoniae, extending assessment to the
Routine set meant that their MDR classification was based on
three additional antibiotic classes (Table 1). The Routine set-
based MDR status performed much better than categorisation
based on the EARS-Net set alone. In contrast, comparing the
Routine and ARPEC sets’ MDR status, only very few addi-
tional isolates were identified as MDR when the more com-
plete ARPEC set was used.
Identification of MDR status based on specific
pathogen–drug combinations
The specific PACCs of interest were E. coli and higher-
generation cephalosporins, fluoroquinolones, aminoglyco-
sides and carbapenems (reported for 98, 99, 98 and 97% of
isolates, respectively), K. pneumoniae and higher-generation
cephalosporins and carbapenems (reported for 99 and 99% of
isolates, respectively), and P. aeruginosa and carbapenems
(reported for 98% of isolates).
Escherichia coli had the following PACC non-
susceptibility profiles based on reported AST results: 13%
(95% CI 9–16%) for third- and fourth-generation cephalospo-
rins, 13% (95% CI 10–18%) for fluoroquinolones, 13% (95%
CI 10–17%) for aminoglycosides and <1% (95% CI 0.1–2%)
for carbapenems. For K. pneumoniae, resistance percentages
for third- and fourth-generation cephalosporins were 32%
(95% CI 25–40%) and for carbapenems 6% (95% CI 3–
11%). Pseudomonas aeruginosa isolates showed 30%
antipseudomonal cephalosporin resistance (95% CI 22–
38%) and 31% carbapenem resistance (95% CI 24–40%).
Resistance to higher-generation cephalosporins was 21%
(95% CI 18–24%) for all three species. The corresponding
resistance percentage for carbapenems was 8% (95% CI 6–
11%).
Figure 2 displays the number and percentage of isolates
that would be appropriately classified as MDR for each
PACC. Isolates are classified as MDR on the basis of the
ARPEC set.
For E. coli, resistance to the specified PACCs failed to
correctly identify MDR status for more than half of the iso-
lates. Aminoglycosides had the best sensitivity (i.e. ability to
identify MDR when it was present) of 41% (Table 3).
Escherichia coli carbapenem resistance was very rare in the
ARPEC dataset, in contrast to MDR E. coli, and was of very
little value in identifying MDR E. coli.
For K. pneumoniae, both cephalosporin and carbapenem
resistance were more strongly associated with MDR status
Eur J Clin Microbiol Infect Dis
than for E. coli isolates. Third- or fourth-generation cephalo-
sporin resistance had a sensitivity of 85%. However, again,
carbapenem resistance was not predictive of MDR
K. pneumoniae (sensitivity 21%).
For P. aeruginosa, both cephalosporin and carbapenem re-
sistance showed a sensitivity of more than 85% for detecting
MDR isolates. For all three GNB, the specificity (the ability to
exclude MDR when it was absent) of the selected pathogen–
drug combinations was above 90%. Thus, the rate of false
classification of isolates as not MDR based on the absence
of resistance to the PACCs reviewed was low.
Discussion
The surveillance definition of MDR requires the availability
of a large number of susceptibility testing results for the cor-
rect classification of isolates [11]. If monitoring and compar-
ison of the prevalence of MDR-GNB is to be an aim for on-
going surveillance activities collecting routine microbiology
AST data, the optimal strategy for detecting MDR organisms
from such data needs to be established. Current surveillance
activities tend to request the AST results for a limited subset of
antibiotic classes listed by the expert MDR classification al-
gorithm [12].
In our dataset, the percentage of MDR-GNB isolates was
significantly lower (13%) when based on a more limited set of
antibiotic classes, such as that used by EARS-Net, compared
with the full set available (30%). Utilising the full set of anti-
biotic classes reportable as part of the ARPEC project, the
proportion of paediatric MDR E. coli, K. pneumoniae and
P. aeruginosa isolates was around 30% and similar for all
three pathogens. Such high levels of isolates with resistance
to multiple drugs are concerning and of interest for tracking
the epidemiology of resistant GNB over time.
Our study raises several important points regarding the
potential of capturing MDR-GNB based on currently avail-
able routine microbiology data purely for surveillance:
(1) Routine reporting of AST data by the 19 European lab-
oratories participating in ARPEC only variably included
results for requested antibiotic classes that are part of the
classification algorithms for E. coli, K. pneumoniae and
P. aeruginosa. A direct application of the MDR algo-
rithms is, therefore, not possible.
(2) Limited AST result data also cannot be used to reliably
estimate the proportion of MDR-GNB. As the ARPEC
dataset includes only European isolates, the performance
of the current European surveillance system was evalu-
ated. The EARS-Net set of antibiotic classes appeared to
lack sensitivity for detecting MDR-GNB. Inclusion of
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Fig. 1 Number and percentage of
isolates classified as MDR based
on different sets of antibiotic
classes (see Table 1 for definitions
of the sets). The total number of
isolates for each bacterial species
is shown at the top of each bar
Table 2 MDR-GNB percentages based on the EARS-Net, Routine and ARPEC sets (see Table 1 for definitions of the sets)
Total no. of
isolates
MDR isolates
% MDR based on EARS-Net set
(95% CI)
% MDR based on Routine set
(95% CI)
% MDR based on full ARPEC set
(95% CI)
E. coli 375 9.3 (6.6–12.7) 28.5 (24.0–33.4) 31.2 (26.5–36.2)
K. pneumoniae 176 13.6 (8.9–19.6) 27.3 (20.8–34.5) 29.6 (22.9–36.9)
P. aeruginosa 134 24.6 (17.6–32.8) n/a 28.4 (20.9–36.8)
All GNB 685 13.4 (11.0–16.2) 27.4 (24.1–31.0) 30.2 (26.8–33.8)
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additional frequently tested and reported antibiotic clas-
ses increased the detection of MDR E. coli and
K. pneumoniae (from 30% detected by the EARS-Net
set to 90% based on the Routine set for E. coli and from
46 to 92% for K. pneumoniae). This was in contrast to
P. aeruginosa, for which the ARPEC set included only
one additional antibiotic class compared with EARS-Net
reporting.
(3) A small number of individual PACCs currently repre-
sent the typical method for reporting antimicrobial re-
sistance surveillance internationally. Disappointingly,
resistance detected in individual PACCs was not reli-
able in detecting MDR isolates. This was especially
marked for E. coli isolates, for which resistance to
higher-generation cephalosporins, for example, had a
sensi t ivi ty of only 36% for detect ing MDR.
Escherichia coli is the GNB with the largest number
of antibiotic classes in the MDR classification algo-
rithm and in ARPEC reporting. This may increase the
detection of many different resistance combinations,
especially if multiple different resistance phenotypes
occur.
Table 3 Detection of MDR-GNB when specific PACC antimicrobial susceptibility testing results are assumed to represent MDR status. The
percentage of isolates misclassified as MDR or not MDR based on PACC results is compared with MDR based on all ARPEC antibiotic categories
(see Table 1)
MDR classification
No. of MDR correctly
identified
Sensitivity of PACC in
% (95% CI)
No. of not MDR
correctly identified
Specificity of PACC in
% (95% CI)
E. coli Third- or fourth-generation
cephalosporins
41/114 36.0 (27.2–45.5) 254/259 98.1 (95.6–99.4)
Fluoroquinolones 46/115 40.0 (31.0–49.6) 255/258 98.8 (96.6–99.8)
Aminoglycosides 48/116 41.4 (32.3–50.9) 253/259 97.7 (95.0–99.1)
Carbapenems 2/117 1.7 (0.2–6.0) 245/245 100.0 (98.5–100.0)
K. pneumoniae Third- or fourth-generation
cephalosporins
44/52 84.6 (71.9–93.1) 123/135 91.1 (85.0–95.3)
Carbapenems 11/52 21.2 (11.1–34.7) 122/122 100.0 (97.0–100.0)
P. aeruginosa Antipseudomonal
cephalosporins
34/38 89.5 (75.2–97.1) 96/102 94.1 (87.6–97.8)
Carbapenems 33/38 86.8 (71.9–95.6) 96/105 91.4 (84.4–96.0)
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Fig. 2 Number and percentage of isolates identified correctly or
incorrectly as MDR based on individual pathogen–antibiotic class
combinations (PACCs). The white stacks correspond to isolates neither
resistant to the PACC nor identified as MDR on the basis of the ARPEC
set (see Table 1 for definitions). The total number of isolates for each
bacterial species are shown underneath. 3/4GC third- or fourth-generation
cephalosporin, QUIN fluoroquinolone, AMG aminoglycoside, CPM car-
bapenem. For P. aeruginosa, only cephalosporins with antipseudomonal
activity were considered
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Some of the challenges may be explained by the fact that
surveillance collects data primarily generated to inform clini-
cal decision-making: approaches to AST are likely to be guid-
ed by the need to optimally inform patient therapy rather than
by the need to generate a complete AST dataset for MDR
classification. This type of selective AST based on clinical
needs could introduce bias when these data are interpreted
for public health purposes [28]. Bias could be magnified when
laboratories engage in so-called first- and second-line testing:
some antibiotic classes are evaluated only when resistance to
antibiotics included in a first-line panel is detected [16].
Several limitations need to be considered when interpreting
the ARPEC data. ARPEC does not cover all antibiotic classes
recommended in the recent expert proposal [11]. It is, there-
fore, possible that some isolates identified as not MDR in
ARPEC would, in fact, be MDR if AST data for all relevant
classes were available. It is also possible that antibiotic classes
tested for some of the reported isolates were suppressed dur-
ing ARPEC data entry. This seems unlikely, given the relative
uniformity of reporting for each species by each laboratory.
The actual percentages of MDR-GNB reported in this
study should be interpreted with caution, as hospitals
reporting to ARPEC were tertiary institutions with a patient
population not representative of patients in other inpatient
settings and potentially at higher risk of MDR-GNB [20,
21]. Pooling of data prohibits the identification of any differ-
ences between individual participating centres, some of which
may have had higher or lower than average MDR-GNB per-
centages. Finally, the burden of MDR-GNB cannot be esti-
mated because data are presented as resistance percentages
rather than infection prevalence or incidence [29].
All isolates represent neonatal or paediatric blood
cultures. The antibiotics used to treat bloodstream infec-
tions in neonates and children may differ from treatment
choices for adults. This could be reflected in the antibi-
otic classes selected for AST, potentially limiting the
transferability of the results to isolates from adults.
However, most laboratories process microbiological
samples from both adult and childhood patients. It is
unlikely that AST strategies will be relevantly different
for neonatal and paediatric isolates in these settings.
Surveillance of antimicrobial resistance patterns and trends
is necessary to target interventions to reduce the selection and
spread of resistant bacteria, and often relies on routine samples
collected as part of on-going clinical care. The limitations and
biases associated with the use of routine microbiology data in
surveillance have been widely discussed [8, 28, 29].
Resistance percentages of individual PACCs and the EARS-
Net set currently in use in Europe do not, on the whole, pro-
vide reliable MDR estimates. This study shows that, if MDR
surveillance is to be added to the task list of on-going interna-
tional surveillance, interpretation of the new algorithm will be
limited by the variability in AST strategies in microbiological
laboratories. MDR-GNB detection could be immediately im-
proved by added surveillance of antibiotic classes already
widely tested as part of clinical care. As demonstrated, a larger
percentage of MDR-GNB isolates is likely to be identified
with such an approach.
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